|
1) Hedner U. Recombinant factor VIIa: its background, development and clinical use. Curr Opin Hematol. 2007; 14: 225-9
|
|
|
|
2) Kenet G. High-dose factor VIIa therapy in hemophilia patients with inhibitors. Semin Hematol. 2006; 43: S108-10
|
|
|
|
|
3) Solomon O, Zivelin A, Livnat T, et al. Inhibitors to factor XI in patients with severe factor XI deficiency. Semin Hematol. 2006; 43: 510-2
|
|
|
|
|
|
4) White GC. Congenital and acquired platelet disorders: current dilemmas and treatment strategies. Semin Hematol. 2006; 43: 537-41
|
|
|
|
|
|
5) Aquilar C, Lucia J. Successful control of severe post-operative bleeding in a case of refractory idiopathic thrombocytopenia ouroura. Am J Hematol. 2007; 82: 246-7
|
|
|
|
|
|
6) Ingerslev J, Vanek T, Culic S. Use of recombinant factor VIIa for emergency reversal of anticoagulation. J Postgrad Med. 2007; 53: 17-22
|
|
|
|
|
|
7) Oh JJ, Akers WS, Lewis D, et al. Recombinant factor VIIa for refractory blleding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepisuden. Pharmacotherapy. 2006; 26: 569-77
|
|
|
|
|
|
8) Rizoli SB, Boffars KD, Riou B, et al. Recombinant factor VIIa as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials. Crit Care. 2006; 10: R178
|
|
|
|
|
|
9) Thoma GO, Dutton RP, Hemlock B, et al. Thromboembolic complications associated with factor VIIa administration. J Trauma. 2005; 62: 564-9
|
|
|
|
|
|
10) Martinowitz U, Michaelson M. Guideline for the use of recombinant activated factor VII(rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidiscriplinary rFVIIa Task Force. J Thromb Haemost. 2005; 3: 640-8
|
|
|
|
|
|
11) Mayer SA. Recombinant factor VII for acute intracerebral hemorrhage. Stroke. 2007; 38: 763-7
|
|
|
|
|
|
12) Mayer SA, Brun NC, Begtrup K, et al. Recombinant factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005; 352: 777-85
|
|
|
|
|
|
13) Chino J, Paolini D, Tran A, et al. Recombinant factor VII as an adjunct to packing for liver injury with hepatic venous disruption. Am Surg. 2005; 71: 595-7
|
|
|
|
|
|
14) Marti-Carvajal AJ, Salanti G, Marti-Carvajal PI. Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases. Cochrane Database Syst Rev. 2007; 24: CD004887
|
|
|
|
|
|
15) Sallah S, Isaksen M, Seremeritis S, et al. Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity-a rebuttal. J Thromb Haemost. 2005; 3: 820-2
|
|
|
|
|
|
16) O'Connnell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006; 296: 43-4
|
|
|
|
|